Financial Performance - For the financial year ended June 30, 2021, the Group reported revenue of approximately S$10.3 million, a gross profit of approximately S$2.6 million, and a profit before taxation of approximately S$0.6 million[8]. - The Group's revenue for the Review Year was approximately S$10.3 million, representing an increase of approximately S$2.7 million, or 34.6%, compared to approximately S$7.6 million for the year ended 30 June 2020[19]. - Revenue from integrated design and building services was approximately S$9.9 million, an increase of approximately S$2.7 million, or 38.4%, compared to approximately S$7.2 million for the year ended 30 June 2020[20]. - The Group's gross profit was approximately S$2.6 million for the Review Year, with a gross profit margin of approximately 25.0%, up from 18.9% in 2020[23]. - Other income for the Review Year was approximately S$0.6 million, or 6.2% of revenue, compared to 7.6% of revenue in the previous year[25]. - Administrative expenses increased by approximately S$0.6 million or 27.6% to approximately S$2.7 million, representing 25.8% of revenue for the Review Year[27]. - The Group recorded a profit of approximately S$0.25 million for the Review Year, compared to a profit of approximately S$0.06 million for the year ended 30 June 2020[29]. - Total shareholders' funds amounted to approximately S$27.8 million as at 30 June 2021, down from approximately S$28.5 million as at 30 June 2020[30]. - The Group's gearing ratio was 0.01% as of June 30, 2021, compared to 0.2% on June 30, 2020[33]. - The Group's aggregate amount of reserves available for distribution to shareholders was approximately S$10.6 million as of June 30, 2021, compared to approximately S$10.3 million in 2020[173]. Business Development and Opportunities - The Singapore government's healthcare expenditure is projected to increase from S$21 billion in 2018 to S$59 billion by 2030, indicating potential growth opportunities for the Group in medical shielding construction[9]. - The Group plans to explore emerging building technologies to strengthen its market position in the medical and healthcare sectors in Singapore while also expanding its presence in Hong Kong and other areas[10]. - The Board is actively seeking new business opportunities and markets with growth potential to diversify the Group's business development[13]. - The Group is developing potential business opportunities in Asia, including software development related to market analytical data for capital markets and other asset classes[10]. Staffing and Expenses - Total staff costs for the Review Year amounted to approximately S$3.3 million, an increase from approximately S$2.8 million in 2020[43]. - The Group employed a total of 70 full-time employees as of June 30, 2021, up from 46 full-time employees as of June 30, 2020[43]. Corporate Governance - The company has adopted all code provisions in the Corporate Governance Code as its own governance practices[81]. - The company complied with the Corporate Governance Code provisions during the review year, except for code provision A.2.1[82]. - The Board is responsible for day-to-day operations, business development, project management, and financial performance evaluation[88]. - The Board currently consists of two executive directors, one non-executive director, and three independent non-executive directors[89]. - The company is committed to high standards of corporate governance to safeguard shareholder interests and enhance corporate value[81]. - The Board regularly reviews the effectiveness of risk management and internal control systems[88]. - The Company aims to develop a robust risk management and internal control system to manage operational and financial risks[134]. - The Company does not currently have an internal audit function due to its simple corporate structure and operations in only one geographical location[142]. Shareholder Information - The Company has adopted a dividend policy that allows shareholders to participate in profits while retaining adequate reserves for future growth[181]. - The Board will consider various factors, including the financial condition of the Group and future cash requirements, when proposing dividends[182]. - Flourish Nation owns 73% of the Company, and is 100% owned by Mr. Lin[191]. - Mr. Lin holds a beneficial interest in 584,000,000 shares, representing 73% of the Company[194]. - As of June 30, 2021, no other Directors or chief executives had interests or short positions in the Company's shares or debentures[192]. - The Company was not involved in any arrangements to enable Directors to acquire benefits through shares or debentures during the Review Year[200]. Risk Management - The Group manages foreign exchange risk by closely monitoring currency rate movements, as it transacts mainly in Singapore dollars but holds balances in multiple currencies[39]. - The Company regularly assesses and reviews its risk management and internal control processes to identify and manage significant risks[137]. - The external internal control reviewer collaborates with the management team to improve any material deficiencies in control[141]. - The Audit Committee is responsible for reviewing risk management and internal control systems, financial policies, and compliance with corporate governance codes[128]. Investments and Acquisitions - The net proceeds from the Listing were approximately HK$74.0 million, intended for various applications including property acquisition and manpower strengthening[47]. - The Group utilized net proceeds of HKD 34 million for the acquisition of additional property for workshop and office use, expected to be completed on or before June 30, 2022[50]. - A total of HKD 21.5 million was allocated for recruiting additional staff, with HKD 9.446 million already spent as of June 30, 2021[50]. - The acquisition of additional motor vehicles and machinery accounted for HKD 5.1 million, with HKD 850 thousand spent to date[50]. Compliance and Regulations - The Company has maintained compliance with relevant laws and regulations during the Review Year[165]. - The Company ensures compliance with the Guidelines on Disclosure of Inside Information and regularly reminds Directors and employees about these policies[138].
HKE HOLDINGS(01726) - 2021 - 年度财报